May 15 (Reuters) - Cabaletta Bio Inc CABA.O:
CABALETTA BIO ANNOUNCES 2027 RESE-CEL BLA SUBMISSION ANTICIPATED IN MYOSITIS FOLLOWING RECENT FDA ALIGNMENT ON REGISTRATIONAL COHORTS
CABALETTA BIO INC: SLE AND LN REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 3Q25
CABALETTA BIO INC: SYSTEMIC SCLEROSIS REGISTRATIONAL DISCUSSIONS WITH FDA ANTICIPATED IN 4Q25
Source text: ID:nGNX2zGZHw
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.